Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2009 March;55(1) > Minerva Gastroenterologica e Dietologica 2009 March;55(1):23-35

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  HEPATOLOGY IN 2009


Minerva Gastroenterologica e Dietologica 2009 March;55(1):23-35

language: English

The management of hepatitis C

Pan J.-J., Firpi R. J.

Section of Hepatobiliary Diseases and Liver Transplantation Division of Gastroenterology, Hepatology and Nutrition Department of Medicine, University of Florida, Gainesville, FL, USA


PDF  


Hepatitis C is a serious public health problem with more than 170 million chronic carriers worldwide. Although hepatitis C infection can be cured in up to 40% of patients, current treatment is not ideal and is associated with a wide spectrum of side effects and complications. Therefore, emerging evidence suggests that patients can receive tailored therapy based on their viral kinetic changes during treatment. With better knowledge of hepatitis C viral genome and life cycle, compounds so called “Specifically Targeted Antiviral Therapy for HCV or STAT-C” are under development. This review will discuss current therapies and recent advances in new therapies for hepatitis C.

top of page

Publication History

Cite this article as

Corresponding author e-mail